Takenami T, Maeda S, Karasawa H, et al. Novel biomarkers distinguishing pancreatic head cancer from distal cholangiocarcinoma based on proteomic analysis. BMC Cancer. 2019;19:318.

PubMed  PubMed Central  Google Scholar 

Center for Cancer Control and Information Services, National Cancer Center, 2020: Monitoring of Cancer Incidence in Japan—Survival 2009–2011 report.

National Comprehensive Cancer Network. NCCN Guidelines Version 3.2021, Pancreatic Adenocarcinoma.2024. https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf Accessed 6 Nov 2024.

Nakachi K, Ikeda M, Konishi M, et al. Adjuvant S-1 compared with observation in resected biliary tract cancer (JCOG1202, ASCOT): a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet. 2023;401:195–203.

CAS  PubMed  Google Scholar 

Primrose JN, Fox RP, Palmer DH, et al. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. Lancet Oncol. 2019;20:663–73.

CAS  PubMed  Google Scholar 

Katoh M, Nakagama H. FGF receptors: cancer biology and therapeutics. Med Res Rev. 2013;34:280–300.

PubMed  Google Scholar 

Touat M, Ileana E, Postel-Vinay S, et al. Targeting FGFR signaling in cancer. Clin Cancer Res. 2015;21:2684–94.

CAS  PubMed  Google Scholar 

Abou-Alfa GK, Sahai V, Hollebecque A, et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol. 2020;21:671–84.

CAS  PubMed  PubMed Central  Google Scholar 

Goyal L, Meric-Bernstam F, Hollebecque A, et al. Futibatinib for FGFR2-rearranged intrahepatic cholangiocarcinoma. N Engl J Med. 2023;388:228–39.

CAS  PubMed  Google Scholar 

Brierley JD, Gospodarowicz MK, Wittekind C, editors. UICC: TNM classification of malignant tumours. 8th ed. Hoboken: Wiley Blackwell; 2017.

Google Scholar 

van Roessel S, Soer EC, Daamen LA, et al. Preoperative misdiagnosis of pancreatic and periampullary cancer in patients undergoing pancreatoduodenectomy: a multicentre retrospective cohort study. Eur J Surg Oncol. 2021;47:2525–32.

PubMed  Google Scholar 

Ney JT, Zhou H, Sipos B, et al. Podocalyxin-like protein 1 expression is useful to differentiate pancreatic ductal adenocarcinomas from adenocarcinomas of the biliary and gastrointestinal tracts. Hum Pathol. 2007;38:359–64.

CAS  PubMed  Google Scholar 

Hooper JE, Morgan TK, Grompe M, et al. The novel monoclonal antibody HPC2 and N-cadherin distinguish pancreatic ductal adenocarcinoma from cholangiocarcinoma. Hum Pathol. 2012;43:1583–9.

CAS  PubMed  Google Scholar 

Lok T, Chen L, Lin F, et al. Immunohistochemical distinction between intrahepatic cholangiocarcinoma and pancreatic ductal adenocarcinoma. Hum Pathol. 2014;45:394–400.

CAS  PubMed  Google Scholar 

Umemoto K, Yamamoto H, Oikawa R, et al. The molecular landscape of pancreatobiliary cancers for novel targeted therapies from real-world genomic profiling. J Natl Cancer Inst. 2022;114:1279–86.

PubMed  PubMed Central  Google Scholar 

ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium. Pan-cancer analysis of whole genomes. Nature. 2020;578:82–93.

Google Scholar 

Cao L, Huang C, Cui Zhou D, et al. Proteogenomic characterization of pancreatic ductal adenocarcinoma. Cell. 2021;184:5031-5052.e26.

CAS  PubMed  PubMed Central  Google Scholar 

Bailey P, Chang DK, Nones K, et al. Genomic analyses identify molecular subtypes of pancreatic cancer. Nature. 2016;531:47–52.

CAS  PubMed  Google Scholar 

Jusakul A, Cutcutache I, Yong CH, et al. Whole-genome and epigenomic landscapes of etiologically distinct subtypes of cholangiocarcinoma. Cancer Discov. 2017;7:1116–35.

CAS  PubMed  PubMed Central  Google Scholar 

Omori Y, Aoki S, Ono Y, et al. Clonal analysis of metachronous double biliary tract cancers. J Pathol. 2024;263:113–27.

PubMed  Google Scholar